Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro

ResearchSpace/Manakin Repository

Show simple item record

dc.contributor.author Bell, Deanna en
dc.contributor.author Liu, Johnson en
dc.contributor.author Tingle, Malcolm en
dc.contributor.author Rattel, B en
dc.contributor.author Meyer, TU en
dc.contributor.author McKeage, Mark en
dc.coverage.spatial Christchurch, New Zealand en
dc.date.accessioned 2012-05-15T01:39:52Z en
dc.date.issued 2008-08-05 en
dc.identifier.citation Joint meeting of New Zealand Society of Oncology, Medical Oncology Group of Australia and Faculty of Radiation Oncologists, Christchurch, New Zealand. 05 Aug 2008 en
dc.identifier.uri http://hdl.handle.net/2292/17981 en
dc.description.abstract 1. Satraplatin is an investigational orally administered platinum-based antitumour drug. The present study compared the plasma protein binding, stability and degradation of satraplatin with that of its active metabolite JM118 and cisplatin. 2. The platinum complexes were incubated in human plasma for up to 2 h at 37°C and quantified in plasma fractions by inductively coupled plasma–mass spectrometry on- or off-line to high-performance liquid chromatography. 3. All three platinum drugs became irreversibly bound to plasma proteins and showed negligible reversible protein binding. They were also unstable in plasma and generated one or more platinum-containing degradation products during their incubation. However, the three platinum complexes differed in the kinetics of their instability and protein binding, as well as in the number of degradation products formed during their incubation. 4. In conclusion, the plasma protein binding, instability and degradation of satraplatin and its active metabolite JM118 are qualitatively similar to that of cisplatin and other clinically approved platinum-based drugs. Quantitative differences in their irreversible protein binding and degradation were related to their respective physiochemical properties and bioactivation mechanisms. Key words: cancer chemotherapy, cisplatin, HPLC–ICP–MS, JM216, plasma stability, platinum-based drugs, protein binding, satraplatin. en
dc.relation.ispartof Joint meeting of New Zealand Society of Oncology, Medical Oncology Group of Australia and Faculty of Radiation Oncologists en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro en
dc.type Conference Item en
dc.identifier.doi 10.1111/j.1440-1681.2008.05017.x en
dc.rights.holder Copyright: The Authors; Blackwell Publishing Asia Pty Ltd en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Abstract en
pubs.elements-id 214998 en
pubs.org-id Medical and Health Sciences en
pubs.org-id Medical Sciences en
pubs.org-id Pharmacology en
pubs.org-id Science en
pubs.org-id Science Research en
pubs.org-id Maurice Wilkins Centre (2010-2014) en
pubs.record-created-at-source-date 2010-09-01 en


Full text options

Full text for this item is not available in ResearchSpace.

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Advanced Search

Browse